A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 May 2015

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Gastrointestinal disorders; Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Soligenix
  • Most Recent Events

    • 19 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 Jan 2014 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCBMT1381).
    • 10 Jan 2014 New source identified and integrated, ClinicalTrials.gov: US National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top